Fate Therapeutics (FATE) Accumulated Depreciation (2014 - 2025)

Fate Therapeutics (FATE) has 12 years of Accumulated Depreciation data on file, last reported at $36.2 million in Q4 2025.

• Quarterly Accumulated Depreciation rose 3.09% year-over-year to $36.2 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $36.2 million (up 3.09% YoY) and the FY2025 annual result came in at $36.2 million, up 3.09% from the prior year.
• Accumulated Depreciation rose to $36.2 million in Q4 2025, from $35.1 million in the prior quarter.
• In the past five years, Accumulated Depreciation ranged from a high of $47.6 million in Q4 2023 to a low of $16.9 million in Q4 2021.
• A 5-year average of $33.3 million and a median of $35.1 million in 2024 frame the typical range for Accumulated Depreciation.
• Annual changes were most pronounced in 2022 — Accumulated Depreciation jumped 79.31% — and 2024, when it dropped 26.23%.
• Tracing FATE's Accumulated Depreciation over 5 years: stood at $16.9 million in 2021, then jumped by 79.31% to $30.4 million in 2022, then jumped by 56.75% to $47.6 million in 2023, then slipped by 26.23% to $35.1 million in 2024, then gained by 3.09% to $36.2 million in 2025.
• The last three Accumulated Depreciation figures came in at $36.2 million (Q4 2025), $35.1 million (Q4 2024), and $47.6 million (Q4 2023), per Business Quant data.